Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3043% below fair value
$25.32+0.37 (+1.48%)
Close on Nov 13, 2026Market cap $824.31MP/E 25.3Yield –
Collegium Pharmaceutical operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Collegium Pharmaceutical's operating cash flow for the twelve months ending Sep 30, 2026 was $338.02M, up 16.2% year over year. For fiscal 2025 it was $329.32M, up 60.7% from the year before. The highest annual figure on record is $329.32M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $329.32M | +60.7% |
| FY2024 | Dec 31, 2024 | $204.98M | -25.4% |
| FY2023 | Dec 31, 2023 | $274.75M | +121.2% |
| FY2022 | Dec 31, 2022 | $124.23M | +20.0% |
| FY2021 | Dec 31, 2021 | $103.56M | +10.2% |
| FY2020 | Dec 31, 2020 | $93.94M | +238.1% |
| FY2019 | Dec 31, 2019 | $27.78M | -83.6% |
| FY2018 | Dec 31, 2018 | $169.39M | – |
| FY2017 | Dec 31, 2017 | -$67.02M | – |
| FY2016 | Dec 31, 2016 | -$75.05M | – |
| FY2015 | Dec 31, 2015 | -$21.57M | – |
| FY2014 | Dec 31, 2014 | -$17.95M | – |
| FY2013 | Dec 31, 2013 | -$16.53M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $86.54M | +10.3% |
| Q2 FY2026 | Jun 30, 2026 | $71.32M | -1.5% |
| Q1 FY2026 | Mar 31, 2026 | $57.11M | +3.1% |
| Q4 FY2025 | Dec 31, 2025 | $123.05M | +45.4% |
| Q3 FY2025 | Sep 30, 2025 | $78.44M | – |
| Q2 FY2025 | Jun 30, 2025 | $72.44M | +7.5% |
| Q1 FY2025 | Mar 31, 2025 | $55.40M | -10.6% |
| Q4 FY2024 | Dec 31, 2024 | $84.64M | +15.4% |
| Q3 FY2024 | Sep 30, 2024 | -$9.00M | -112.2% |
| Q2 FY2024 | Jun 30, 2024 | $67.40M | -32.4% |
| Q1 FY2024 | Mar 31, 2024 | $61.94M | +123.8% |
| Q4 FY2023 | Dec 31, 2023 | $73.34M | +10.6% |
| Q3 FY2023 | Sep 30, 2023 | $74.02M | +73.1% |
| Q2 FY2023 | Jun 30, 2023 | $99.72M | +146.5% |
| Q1 FY2023 | Mar 31, 2023 | $27.67M | – |
| Q4 FY2022 | Dec 31, 2022 | $66.33M | +83.2% |
| Q3 FY2022 | Sep 30, 2022 | $42.77M | +147.9% |
| Q2 FY2022 | Jun 30, 2022 | $40.45M | +37.0% |
| Q1 FY2022 | Mar 31, 2022 | -$25.32M | -223.1% |
| Q4 FY2021 | Dec 31, 2021 | $36.20M | +60.3% |
| Q3 FY2021 | Sep 30, 2021 | $17.25M | -49.5% |
| Q2 FY2021 | Jun 30, 2021 | $29.54M | -32.7% |
| Q1 FY2021 | Mar 31, 2021 | $20.57M | – |
| Q4 FY2020 | Dec 31, 2020 | $22.58M | +44.2% |
| Q3 FY2020 | Sep 30, 2020 | $34.18M | +463.2% |
| Q2 FY2020 | Jun 30, 2020 | $43.85M | +199.8% |
| Q1 FY2020 | Mar 31, 2020 | -$6.67M | – |
| Q4 FY2019 | Dec 31, 2019 | $15.66M | -63.0% |
| Q3 FY2019 | Sep 30, 2019 | $6.07M | -85.5% |
| Q2 FY2019 | Jun 30, 2019 | $14.63M | -73.7% |
| Q1 FY2019 | Mar 31, 2019 | -$8.57M | -128.9% |
| Q4 FY2018 | Dec 31, 2018 | $42.29M | – |
| Q3 FY2018 | Sep 30, 2018 | $41.83M | – |
| Q2 FY2018 | Jun 30, 2018 | $55.61M | – |
| Q1 FY2018 | Mar 31, 2018 | $29.66M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$17.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.69M | – |
| Q4 FY2016 | Dec 31, 2016 | -$23.29M | – |
See a number that looks wrong?